DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer.
Ontology highlight
ABSTRACT: Alterations in DNA damage response (DDR) and related genes are present in up to 25% of advanced prostate cancers (PCa). Most frequently altered genes are involved in the homologous recombination repair, the Fanconi anemia, and the mismatch repair pathways, and their deficiencies lead to a highly heterogeneous spectrum of DDR-deficient phenotypes. More than half of these alterations concern non- BRCA DDR genes. From a therapeutic perspective, poly-ADP-ribose polymerase inhibitors have demonstrated robust clinical efficacy in tumors with BRCA2 and BRCA1 alterations. Mismatch repair-deficient PCa, and a subset of CDK12-deficient PCa, are vulnerable to immune checkpoint inhibitors. Emerging data point to the efficacy of ATR inhibitors in PCa with ATM deficiencies. Still, therapeutic implicatio
SUBMITTER: Akhoundova D
PROVIDER: S-EPMC10846598 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA